Julia Rotow, MD, clinical director of the Lowe Center for Thoracic Oncology shares an overview of EGFR-mutant lung cancer and discusses ...

YouTube-Dana-Farber Cancer Institute

EGFR mutations are the most commonly occurring mutation in non-small cell lung cancer (NSCLC) and occur in approximately 50% of Asian NSCLC.

YouTube-VJOncology

Pasi A. Jänne, MD, PhD, director of the Chen-Huang Center for EGFR-Mutant Lung Cancers, discusses research and treatment developments at the ...

YouTube-Dana-Farber Cancer Institute

Reporting from ESMO Congress 2023 in Madrid, Marina Garassino discusses the results from two important studies on combination treatments in ...

YouTube-European Society for Medical Oncology (ESMO)

Masahiro Tsuboi, MD, National Cancer Center Hospital East, Chiba, Japan, discusses when and to whom to administer tyrosine kinase inhibitor ...

YouTube-VJOncology

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician ...

YouTube-PeerView Oncology

Michelle Jacobo, PhD, Director of Psychology, of Dana-Farber's Psychosocial Oncology & Palliative Care, explains how the Gilboard Family ...

YouTube-Dana-Farber Cancer Institute

This video is either unavailable or not supported in this browser · First- and second-generation EGFR tyrosine kinase inhibitors (TKIs) for EGFR mutation- ...

Research To Practice